Human Immunodeficiency Virus | Current Treatment | US | 2016

The Human Immunodeficiency Virus (HIV) market is seeing growth due to the uptake of new premium-priced antiretroviral agents, particularly the latest single-tablet regimens (STRs) with improved side-effect profiles that place an emphasis on safety and tolerability. Our Current Treatment content provides deep insights drawn from a survey of 103 infectious disease specialists and internal medicine physicians regarding the current and anticipated use of HIV regimens, including the recently approved STR Genvoya (elvitegravir/emtricitabine/tenofovir alafenamide/cobicistat), by capturing patient and market share data, current prescribing trends, and anticipated changes in prescribing and treatment behavior in the United States today.

Login to access report